Ani Pharmaceuticals INC

ANI Pharmaceuticals stockholders approved the Amended and Restated 2022 Stock Incentive Plan and ratified the appointment of Ernst & Young LLP as auditor at the company's 2026 Annual Meeting.

ANI Pharmaceuticals, Inc. has published an updated investor presentation, projecting approximately $1.1 billion in total net revenue for 2026, with its Rare Disease business expected to constitute about 60% of total revenues.

ANI Pharmaceuticals announced robust first-quarter 2026 financial results, exceeding expectations with a 20.5% year-over-year revenue increase and raising its full-year financial guidance.

ANI Pharmaceuticals, Inc. announced the dismissal of EisnerAmper LLP and the appointment of Ernst & Young LLP as its new independent registered public accounting firm.

ANI Pharmaceuticals forecasts significant revenue and profit growth for 2026, fueled by its expanding Rare Disease segment and strong performance from Cortrophin Gel.

ANI Pharmaceuticals announced record fourth quarter and full year 2025 financial results, driven by strong growth in its Rare Disease and Generics segments, and reaffirmed robust 2026 financial guidance.

ANI Pharmaceuticals announces a 20.5% increase in net revenues for Q1 2026, driven by its Rare Disease and Brands segment, with significant growth in Cortrophin Gel and ILUVIEN sales.

ANI Pharmaceuticals delivered significant revenue and net income growth in Q3 2025, driven by its Rare Disease and Brands segment and recent acquisitions.

ANI Pharmaceuticals reports significant revenue and profit growth in Q2 2025, driven by its Rare Disease and Brands segments and successful integration of Alimera Sciences.

ANI Pharmaceuticals' Q1 2025 net revenues increased by 43.4% year-over-year, driven by the acquisition of Alimera and growth in generic pharmaceutical products.

ANI Pharmaceuticals' Q3 2024 results reflect a net loss, increased operating expenses, and the impact of the recent Alimera acquisition, alongside a significant increase in rare disease revenue.

ANI Pharmaceuticals' Q2 2024 results show increased revenue driven by rare disease products, but a net loss due to acquisition costs and other factors.

ANI Pharmaceuticals achieved significant revenue and net income growth in 2025, fueled by the successful integration of Alimera Sciences and key product expansions.

ANI Pharmaceuticals' 2024 results reflect a year of strategic acquisition and mixed financial performance, highlighted by the integration of Alimera Sciences and ongoing challenges in the generics market.

ANI Pharmaceuticals modifies its stock incentive plan and releases its 2023 annual report, highlighting growth in rare disease and generics segments.

Stephen P. Carey, SVP & CFO of Ani Pharmaceuticals Inc, sold 2,850 shares of common stock on July 29, 2026 for $81.36 per share.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of Ani Pharmaceuticals Inc, reported a transaction in 2,466 shares of common stock on July 18, 2026.

Meredith Cook, SR. VP, GENERAL COUNSEL & SEC. of Ani Pharmaceuticals Inc, sold 500 shares of common stock on July 13, 2026 for $81.84 per share.

ANI Pharmaceuticals SVP & CFO Stephen P. Carey executed a Rule 10b5-1 plan, exercising stock options and selling shares.

ANI Pharmaceuticals SVP & CFO Stephen P. Carey sold 2,850 shares of common stock valued at approximately $239,670, as part of a pre-arranged trading plan.

Meredith Cook, Senior VP and General Counsel at ANI Pharmaceuticals, sold 500 shares of common stock.

ANI Pharmaceuticals, Inc. convened its 2026 Annual Meeting of Stockholders, highlighting record 2025 financial performance driven by its Rare Disease segment and strong Generics business.

ANI Pharmaceuticals supplements its proxy statement to clarify information regarding its Amended and Restated 2022 Stock Incentive Plan, specifically detailing non-shareholder approved inducement grants.

ANI Pharmaceuticals has filed a definitive proxy statement with the SEC.

ANI Pharmaceuticals announces strong 2024 results with a 26% increase in total revenue and a 17% rise in adjusted non-GAAP EBITDA, driven by its Rare Disease business and strategic acquisitions.

ANI Pharmaceuticals has filed definitive additional materials related to its proxy statement with the SEC.

ANI Pharmaceuticals achieved record financial performance in 2023, with significant revenue and EBITDA growth driven by its Rare Disease and Generics businesses.

Meridian Venture Partners and Robert E. Brown, Jr. updated their beneficial ownership in ANI Pharmaceuticals, Inc., collectively holding 4.8% of common stock.

Meridian Venture Partners and affiliated entities, along with Robert E. Brown, Jr., have filed an amended Schedule 13D, disclosing the sale of 50,000 shares of ANI Pharmaceuticals, Inc. common stock for investment purposes.

The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in ANI Pharmaceuticals Inc. following an internal corporate realignment.

Millennium Management and affiliated entities have disclosed beneficial ownership of up to 0.3% of ANI Pharmaceuticals, Inc. common stock as of September 30, 2025.

BlackRock, Inc. has reported an 11.3% beneficial ownership stake in ANI Pharmaceuticals Inc. common stock, holding 2,517,424 shares.

Millennium Management LLC and affiliated entities have disclosed a passive beneficial ownership of 5.2% of ANI Pharmaceuticals, Inc.'s common stock, as detailed in a recent Schedule 13G filing.

Millennium Management LLC and its affiliates have reported a 3.8% beneficial ownership stake in ANI Pharmaceuticals, Inc. as of March 31, 2025.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly disclosed a 5.2% beneficial ownership stake in ANI Pharmaceuticals, Inc., totaling 1,091,003 shares.